$542 MillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$90.1 MillionTotal revenue in the last quarter.
$-176 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-3.01Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-1.26xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-58.3 MillionEarnings before interest expenses and taxes in the last quarter.
360The number of full time employees.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) dropped 7.8% during mid-day trading on Wednesday . The stock traded as low as $3.29 and last traded at $3.30. Approximately 4,452,880 shares traded h...The Olympia Report, 1 day ago
Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.Yahoo Finance, 9 days ago
https://www.investing.com/news/stock-market-news/baupost-group-dumps-akebia-therapeutics-inc-2320887Investing.com, 13 days ago